The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
Φόρτωση...
Ημερομηνία
Συγγραφείς
Filippatos, T. D.
Gazi, I. F.
Liberopoulos, E. N.
Athyros, V. G.
Elisaf, M. S.
Tselepis, A. D.
Kiortsis, D. N.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Atherosclerosis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Increased concentration of small dense LDL cholesterol (sdLDL-C) and activity of lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are considered as emerging cardiovascular risk factors and are commonly encountered in subjects with metabolic syndrome (MetS). OBJECTIVE: The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS. METHODS: Patients (n=89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200mg/day (F group) or both (OF group) for 6 months. RESULTS: Significant reductions of sdLDL-C levels were observed in all treatment groups. Groups F and OF experienced a greater reduction in sdLDL-C levels (p<0.05) together with a greater increase in LDL particle diameter (p<0.05) compared with group O. Total plasma Lp-PLA(2) activity significantly decreased in all treatment groups. The reduction of Lp-PLA(2) was more pronounced with OF administration compared with each monotherapy (p<0.05). CONCLUSION: Orlistat and fenofibrate exhibited favorable effects on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients with MetS. Importantly, combination treatment had a more favorable effect on these risk factors.
Περιγραφή
Λέξεις-κλειδιά
1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood, Adult, Anti-Obesity Agents/pharmacology/therapeutic use, Cardiovascular Diseases/drug therapy/etiology, Cholesterol, LDL/*blood, Drug Therapy, Combination, Female, Fenofibrate/pharmacology/*therapeutic use, Humans, Hypolipidemic Agents/pharmacology/therapeutic use, Lactones/pharmacology/*therapeutic use, Male, Metabolic Syndrome X/drug therapy/etiology, Middle Aged, Obesity/complications/*drug therapy, Overweight, Phospholipases A2, Risk Factors
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/16911813
http://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc
http://ac.els-cdn.com/S0021915006004084/1-s2.0-S0021915006004084-main.pdf?_tid=d29956a44a96251d298a203a6bbb2079&acdnat=1333531139_a7897d9d8d05921b4cdc9ffe783e74bc
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής